Biora Therapeutics, Inc. (BIOR)
USD 0.22
(0.0%)
USD 0.22
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 67.14 Million USD | 7.26% |
| 2022 | 62.08 Million USD | -47.86% |
| 2021 | 119.08 Million USD | -32.36% |
| 2020 | 176.06 Million USD | -4.11% |
| 2019 | 183.61 Million USD | 22.3% |
| 2018 | 150.13 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 15.99 Million USD | 0.29% |
| 2024 Q1 | 16.05 Million USD | 21.4% |
| 2023 Q2 | 14.93 Million USD | -3.92% |
| 2023 FY | 66.59 Million USD | 7.26% |
| 2023 Q3 | 23.32 Million USD | 56.14% |
| 2023 Q1 | 15.54 Million USD | 12.73% |
| 2023 Q4 | 13.22 Million USD | -43.28% |
| 2022 Q3 | 13.96 Million USD | -2.42% |
| 2022 Q2 | 14.31 Million USD | -28.48% |
| 2022 Q1 | 20.01 Million USD | -2.81% |
| 2022 FY | 62.08 Million USD | -47.86% |
| 2022 Q4 | 13.79 Million USD | -1.27% |
| 2021 FY | 119.08 Million USD | -32.36% |
| 2021 Q3 | 30.74 Million USD | -14.88% |
| 2021 Q4 | 20.59 Million USD | -33.01% |
| 2021 Q2 | 36.11 Million USD | -25.6% |
| 2021 Q1 | 48.54 Million USD | 9.77% |
| 2020 Q2 | 42.15 Million USD | -1.48% |
| 2020 Q1 | 42.78 Million USD | -3.83% |
| 2020 FY | 176.06 Million USD | -4.11% |
| 2020 Q4 | 44.22 Million USD | -5.74% |
| 2020 Q3 | 46.91 Million USD | 11.3% |
| 2019 Q4 | 44.48 Million USD | -8.49% |
| 2019 Q2 | 45.41 Million USD | 0.71% |
| 2019 Q1 | 45.09 Million USD | 8.07% |
| 2019 FY | 183.61 Million USD | 22.3% |
| 2019 Q3 | 48.61 Million USD | 7.05% |
| 2018 Q4 | 41.72 Million USD | 0.0% |
| 2018 FY | 150.13 Million USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| America Great Health | 661.23 Thousand USD | -10054.832% |
| Ampio Pharmaceuticals, Inc. | 9.26 Million USD | -624.504% |
| Aridis Pharmaceuticals, Inc. | 29.99 Million USD | -123.876% |
| Bio-Path Holdings, Inc. | 15.84 Million USD | -323.828% |
| Better Therapeutics, Inc. | 38.26 Million USD | -75.493% |
| Calithera Biosciences, Inc. | 40.68 Million USD | -65.025% |
| Comera Life Sciences Holdings, Inc. | 12.39 Million USD | -441.826% |
| Gene Biotherapeutics, Inc. | - USD | -Infinity% |
| eFFECTOR Therapeutics, Inc. | 33.84 Million USD | -98.401% |
| Eloxx Pharmaceuticals, Inc. | 34.41 Million USD | -95.087% |
| Evelo Biosciences, Inc. | 108.46 Million USD | 38.094% |
| Evolutionary Genomics, Inc. | 992.8 Thousand USD | -6663.335% |
| Finch Therapeutics Group, Inc. | 32.58 Million USD | -106.042% |
| Galera Therapeutics, Inc. | 46.95 Million USD | -43.015% |
| Innovation1 Biotech Inc. | 1.21 Million USD | -5427.922% |
| Kiromic BioPharma, Inc. | 19.93 Million USD | -236.757% |
| Molecular Templates, Inc. | 63.09 Million USD | -6.429% |
| Navidea Biopharmaceuticals, Inc. | 13.93 Million USD | -381.976% |
| NexImmune, Inc. | 28.16 Million USD | -138.385% |
| Orgenesis Inc. | 45.75 Million USD | -46.747% |
| Panbela Therapeutics, Inc. | 25.64 Million USD | -161.812% |
| Point of Care Nano-Technology, Inc. | 73.41 Thousand USD | -91360.989% |
| PaxMedica, Inc. Common Stock | 16.14 Million USD | -315.893% |
| Scopus BioPharma Inc. | 11.71 Million USD | -473.177% |
| Sorrento Therapeutics, Inc. | 403.56 Million USD | 83.361% |
| Statera Biopharma, Inc. | 28.82 Million USD | -132.911% |
| TRACON Pharmaceuticals, Inc. | 18.92 Million USD | -254.731% |
| Trevena, Inc. | 38.41 Million USD | -74.803% |
| Vaxxinity, Inc. | 56.05 Million USD | -19.796% |
| Vaccinex, Inc. | 23.45 Million USD | -186.28% |
| Vicapsys Life Sciences, Inc. | 1.04 Million USD | -6313.411% |
| Viracta Therapeutics, Inc. | 50.69 Million USD | -32.458% |
| ZIVO Bioscience, Inc. | 7.27 Million USD | -823.031% |